Year: 2025
Type: article
Abstract: In this issue of Blood, Falchi et al 1 reported the results of arm 2 of EPCORE NHL-2 evaluating fixed-duration epcoritamab with rituximab and lenalidomide (R2) in relapsed/refractory (R/R) follicular lymphoma (FL) in an openlabel, multicenter, phase 1b/2 study.The authors showed that the addition of epcoritamab to R2 was safe with promising signals of efficacy.Epcoritamab is a subcutaneous CD3× CD20 bispecific antibody approved as monotherapy for R/R FL and R/R diffuse large B-cell lymphoma (DLBCL) after ≥2 lines of therapy and administered until progression or unacceptable toxicity.2,3 Epcoritamab monotherapy showed an excellent overall response rate (ORR) of 82% in 128 R/R FL with a complete response (CR) rate of 62.5%.Efficacy of epcoritamab monotherapy was maintained across different subgroups including those with high-risk features.Responses appeared durable with 73.8% of CRs being progression-free at 18 months form treatment initiation and the safety profile was good. 2
Source: Blood
Authors: Umberto Vitolo, Francesca Bonello
Institution: Candiolo Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416746615